MedTrace Logo

Anticoagulation in Patients With Venous Thromboembolism and Cancer

NCT04618913 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2026-03-12

No results posted yet for this study

Summary

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Conditions

  • Neoplasms
  • Embolism

Interventions

DRUG

Apixaban

Anticoagulant

DRUG

Rivaroxaban

Anticoagulant

DRUG

Edoxaban

Edoxaban

DRUG

Dabigatran

Dabigatran

DRUG

VKA

Vitamin K antagonist

DRUG

LMWH

Low Molecular Weight Heparin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2026-04-06
Completion
2026-04-06
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04618913 on ClinicalTrials.gov